Sasayama Mikiko, Deng Lin, Kim Soo-Ryang, Ide Yoshihiro, Shoji Ikuo, Hotta Hak
Division of Microbiology, Center for Infectious Diseases, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe 650-0017, Japan.
Kobe J Med Sci. 2010 Sep 28;56(2):E60-6.
The role of neutralizing antibodies (NAb) in determining responses to antiviral therapy has not been defined well. By using hepatitis C virus (HCV) cell culture system with the J6/JFH1 strain of HCV genotype 2a, we analyzed NAb responses in patients with chronic hepatitis C who received pegylated-interferon plus ribavirin (PEG-IFN/RBV) antiviral therapy. A total of 65 patients chronically infected with HCV genotype 1b were enrolled in this study. Of all the 65 patients, 34 (52%) patients achieved early virological response (EVR), with the remaining 31 patients (48%) being Non-EVR. Twenty-seven patients (42%) achieved sustained virological response (SVR), with the remaining 38 patients (58%) being Non-SVR. Thus, NAb titers were significantly higher in sera of patients who achieved EVR and SVR than those of Non-EVR and Non-SVR, respectively. Rather unexpectedly, NAb titers did not significantly decrease when measured even one year after disappearance of HCV RNA. On the other hand, when change ratios of NAb titers before and after disappearance of HCV RNA were compared between patients with different treatment outcomes, we noticed that the change ratio of NAb titers of patients who achieved an EVR was significantly lower than that of Non-SVR. In conclusion, our present results suggest that NAb titers were significantly associated with clinical responses to PEG-IFN/RBV therapy.
中和抗体（NAb）在确定抗病毒治疗反应中的作用尚未得到很好的界定。通过使用丙型肝炎病毒（HCV）2a基因型J6/JFH1株的细胞培养系统，我们分析了接受聚乙二醇干扰素加利巴韦林（PEG-IFN/RBV）抗病毒治疗的慢性丙型肝炎患者的NAb反应。本研究共纳入65例慢性感染HCV 1b基因型的患者。在这65例患者中，34例（52%）患者实现了早期病毒学应答（EVR），其余31例患者（48%）为非EVR。27例患者（42%）实现了持续病毒学应答（SVR），其余38例患者（58%）为非SVR。因此，实现EVR和SVR的患者血清中的NAb滴度分别显著高于非EVR和非SVR的患者。相当出乎意料的是，即使在HCV RNA消失一年后进行检测，NAb滴度也没有显著下降。另一方面，当比较不同治疗结果患者在HCV RNA消失前后NAb滴度的变化率时，我们注意到实现EVR的患者的NAb滴度变化率显著低于非SVR的患者。总之，我们目前的结果表明，NAb滴度与对PEG-IFN/RBV治疗的临床反应显著相关。
